Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

U.N. says it will investigate source of Haitian cholera epidemic as death toll rises

The U.N. is looking into establishing an independent commission to identify the source of Haiti's cholera epidemic, Alain Le Roy, the U.N. under-secretary-general for peacekeeping operations, said on Wednesday, the Associated Press/Washington Post reports. "We are urging and we are calling for what we could call an international panel," Le Roy said at a news conference at the U.N. headquarters in New York. "We are in discussions with (the U.N. World Health Organization) to find the best experts to be in a panel to be completely independent," he added.

17 Dec 2010

First comprehensive guide to hospital emergency preparedness exercise development

With the publication of the nation's first comprehensive, federally funded guide to hospital emergency preparedness exercise development, Dr. Nathaniel Hupert at Weill Cornell Medical College and his collaborators have provided a new toolset for strengthening hospitals' ability to protect communities nationwide against public health disasters, such as creating care centers during an influenza pandemic or treating casualties in the wake of a bioterrorism attack.

17 Dec 2010

Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010

Accelr8 Technology Corporation announced its financial results for the first fiscal quarter ended October 31, 2010. Net sales revenues totaled $466,362; net income from operations was $49,974 with total net income of $67,250. For the previous quarter, net sales were $15,549 with a loss from operations of $(423,373) and a total net loss of $(411,981). Shareholders' equity totaled $4,985,682 at the current quarter's end, up from $4,909,778 at the end of the previous fiscal quarter.

17 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Carrageenan, is a polymer derived from red seaweed which helps to create a protective physical barrier in the nasal cavity and has proven to be an effective antiviral in the treatment of the common cold.

16 Dec 2010

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Results from a government-sponsored clinical trial of inactivated 2009 H1N1 influenza vaccine in people with asthma indicate that a single dose of vaccine was safe and induced a strong immune response predictive of protection.

14 Dec 2010

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2010.

13 Dec 2010

Haitian cholera pathogen closely related to 'El Tor O1' variant from South Asia

Scientists from Pacific Biosciences of California, Inc. and Harvard Medical School have successfully employed single molecule, real-time (SMRT™) DNA sequencing technology to rapidly characterize the pathogen responsible for the recent deadly cholera epidemic in Haiti. Published online Thursday in the New England Journal of Medicine, the results provide the first whole genome sequence analysis and most detailed genetic profile to date of the Haitian Vibrio cholerae outbreak strain.

10 Dec 2010

Vibrio cholerae evolves two new mechanisms to cause similar disease

New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio-.

9 Dec 2010

Researchers develop statistical model to predict severity of seasonal influenza

Researchers have developed a statistical model for projecting how many people will get sick from seasonal influenza based on analyses of flu viruses circulating that season. The research, conducted by scientists at the National Institutes of Health, appears today in the open-access publication PLoS Currents: Influenza.

9 Dec 2010

Lung transplant saves economist from near-lethal bout of swine flu

According to the critical care experts at The Johns Hopkins Hospital who treated him, Allen Bagents, 24, of Arlington, Va., is the least likely person anyone ever expects to get sick, let alone suffer a six-week, potentially fatal bout with the swine flu, better known as H1N1 influenza.

8 Dec 2010

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi. The event will be hosted by IMAPAC, in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network).

8 Dec 2010

FDLI to launch Food and Drug Policy Forum publication in 2011

In 2011, the Food and Drug Law Institute will launch a new publication — FDLI"s Food and Drug Policy Forum. "The Policy Forum is designed to provide a new electronic marketplace for the exchange of ideas among food and drug law, regulation, and policy professionals," notes Susan C. Winckler, President and CEO of FDLI.

8 Dec 2010

SEEK reports Phase I safety trail for investigational flu vaccine

SEEK, a leading UK privately-owned drug-discovery group, today presented data on the successful conclusion of a Phase I safety and tolerability study for its investigational Universal Influenza Vaccine, FLU-v, at the World Influenza Congress in Amsterdam (7-9 December).

8 Dec 2010

Studies highlight need for new antiviral treatment options and strategies

Two new studies raise public health concerns about increasing antiviral resistance among certain influenza viruses, their ability to spread, and a lack of alternative antiviral treatment options.

7 Dec 2010

Experimental flu vaccine triggers immune response, protects against flu

Vaccine production hinges on the availability of hundreds of millions of eggs - and even with the vaccine, flu still claims somewhere around 36,000 lives in the United States during a typical year.

7 Dec 2010

Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine

Fraunhofer USA Center for Molecular Biotechnology announced today it has received approval from the Food and Drug Administration to proceed with the first human clinical trial of plant-produced H5N1 influenza vaccine.

6 Dec 2010

Patients with H1N1 flu die due to over-reactive immune response: Research

On November 19, Jason Martin returned to the Medical Intensive Care Unit at Vanderbilt University Medical Center for the first time since he nearly died there during last year's H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance worker - a 30-year-old, father of three young children - broke down and hugged some of the nurses he recognized.

6 Dec 2010

IDRI awarded $1.8M contract to develop adjuvant formulations for pandemic influenza

The Infectious Disease Research Institute has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority. IDRI's work will focus on development of adjuvant formulations with options up to $8.5 million over three years when further development and manufacture of priority candidates are approved by the agency.

4 Dec 2010

IDRI receives $790,200 BARDA grant to develop pandemic flu vaccine

The Infectious Disease Research Institute (IDRI) today announced it has received a $790,200 grant from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services. The grant enables technology transfer between IDRI and the Cantacuzino National Institute of Research and Development for Microbiology and Immunology (Bucharest, Romania), with the goal of producing a pandemic flu vaccine.

4 Dec 2010

Pandemic News and Research

Further Reading

U.N. says it will investigate source of Haitian cholera epidemic as death toll rises

First comprehensive guide to hospital emergency preparedness exercise development

Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

Haitian cholera pathogen closely related to 'El Tor O1' variant from South Asia

Vibrio cholerae evolves two new mechanisms to cause similar disease

Researchers develop statistical model to predict severity of seasonal influenza

Lung transplant saves economist from near-lethal bout of swine flu

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

FDLI to launch Food and Drug Policy Forum publication in 2011

SEEK reports Phase I safety trail for investigational flu vaccine

Studies highlight need for new antiviral treatment options and strategies

Experimental flu vaccine triggers immune response, protects against flu

Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine

Patients with H1N1 flu die due to over-reactive immune response: Research

IDRI awarded $1.8M contract to develop adjuvant formulations for pandemic influenza

IDRI receives $790,200 BARDA grant to develop pandemic flu vaccine

Best practices - optimize qPCR processes for pathogen detection eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News